- Source : Business Wire
- Date : 2021-06-16
- Companies : Bayer AG
Bayer Announces First 'Precision Oncology Patient Innovation Awards'
WHIPPANY, N.J.--(BUSINESS WIRE)--As part of a continued commitment to the worldwide cancer community, Bayer announced today the first global 'Precision Oncology Patient Innovation Awards.' The 2021 Awards aim to foster innovation and collaboration to improve access to precision oncology care and tackle inequalities for people with cancer around the world. The Awards are focused on supporting people with cancer types that are known to harbor rare genomic alterations that may benefit from genomic cancer testing.
“Genomic cancer testing can help identify the appropriate patient for which precision oncology has the potential to treat. Information and access to testing is critical to see the impact of precision oncology treatments,” said Joseph Germino, M.D., Vice President of Medical Affairs, Oncology. “Bayer's support of the first global 'Precision Oncology Patient Innovation Awards' demonstrates our continued commitment to the patient community and the need to further this important programming in precision medicine.”
Non-profit organizations, including patient advocacy groups, educational institutions, and officially recognized healthcare and research facilities are invited to enter by 12:00 AM EDT, on June 25, 2021. Two grants – one for $50,000 and a second for $25,000 – will be awarded in 2021 to support a new precision oncology initiative or to support a continued rollout or expansion of an existing program relevant to the pediatric or adult cancer communities. Applications will be reviewed by an independent panel of experts, comprised of leading experts from the clinical and patient advocacy cancer communities.
Precision oncology is a critical and evolving field of research where cancers are tested and treated according to their unique DNA fingerprint. Bayer has played an important role in this field through the development of treatment options and patient programs, and is committed to continuing these research efforts for the cancer community.
For more information about the Awards and how to apply, please visit www.precisiononcologyawards.com/.
About Oncology at Bayer
Bayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments. The oncology franchise at Bayer includes six marketed products and several other assets in various stages of clinical development. Together, these products reflect the company's approach to research, which prioritizes targets and pathways with the potential to impact the way that cancer is treated.
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4 billion euros. R&D expenses before special items amounted to 4.9 billion euros. For more information, go to www.bayer.com.
© 2021 Bayer
BAYER and the Bayer Cross are registered trademarks of Bayer.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
Intended for U.S. Media Only
Rebecca Cowens-Alvarado, Tel. 1 862.341.8103
E-Mail: [email protected]